Boron for Bone Mineral Density

Boron is a trace mineral, found mostly in plant foods, that is often added to bone supplements. There is no good evidence that it raises bone mineral density (BMD), the measure on a DXA scan. The only placebo-controlled trial to measure BMD compared 3 mg a day with placebo for 10 months in 28 young women (17 college athletes and 11 sedentary women), and the supplement did not directly affect their bone density (NIH ODS; Meacham 1994).

Most of the case for boron comes from small metabolic-ward studies in postmenopausal women, in which 3 mg a day after a low-boron diet changed calcium loss in urine or hormone levels in some studies but not others (Nielsen 1987; Beattie 1993; Nielsen 2004). Studies that compare people's boron intake with their bone density disagree (Kim 2008; Rababah 2024). No trial has given boron to people with low bone density and measured whether their BMD changed.

Boron may matter for bone growth and formation, possibly by affecting osteoblasts and osteoclasts (the cells that build and break down bone), steroid hormone levels and calcium metabolism (NIH ODS). A 2012 review placed calcium metabolism and bone growth and maintenance among boron's possible roles in humans but noted that the biochemical mechanisms are poorly understood (Hunt 2012).

Animal work gives the clearest signal. Boron deficiency in animals causes abnormal limb development and lower bone strength, bone volume fraction and trabecular thickness, and supplementing animals on usual or low boron intakes improves some measures of bone strength (NIH ODS). A 2014 review argued that intakes below 1.0 mg a day limit boron's benefits and that people should get more from fruits, vegetables, nuts and pulses (Nielsen 2014).

Bone strength in boron-deprived animals is not the same as bone density in people who already eat some boron. In aged ovariectomised rats (a model of menopause), boric acid at 8.7 mg boron per kg a day for 40 days did not raise BMD of the lumbar spine or upper thigh bone and gave no protection against bone loss; BMD was highest in the rats given oestradiol (Gallardo-Williams 2003).

The human hormone and urine findings are markers, not bone. The body also regulates boron tightly: in 11 postmenopausal women, a 9-fold rise in dietary boron raised plasma boron only 1.5-fold, and nearly all of it was excreted (Hunt 1997). The urine and hormone changes seen with boron have also not been consistent from study to study.

The bone density trial used 3 mg of boron a day for 10 months (NIH ODS), and the metabolic-ward studies in postmenopausal women used the same 3 mg dose, usually after weeks or months on a low-boron diet (Nielsen 1987; Beattie 1993; Hunt 1997). For comparison, median dietary boron intake in US adults is 0.87-1.35 mg a day, and about 1.0-1.5 mg a day including supplements (NIH ODS).

Narrative reviews that favour boron suggest 3 mg a day for bone (Rondanelli 2020; Pizzorno 2015), but no trial has shown that this dose raises BMD, and a 2026 critical review judged human data insufficient to justify supplementation (Melenikioti 2026). Supplement labels state elemental boron; common products contain 0.15-6 mg, in forms such as sodium borate, boron citrate, boron glycinate and calcium fructoborate, and there are no data comparing how well these forms are absorbed (NIH ODS).

Seventeen female college athletes (mean age 19.8) and 11 sedentary women (mean age 20.3) took 3 mg of boron a day or a placebo for 10 months (NIH ODS). Bone mineral density rose slightly in the athletes and fell slightly in the sedentary women (Meacham 1994), but NIH ODS notes that the supplement did not directly affect BMD (NIH ODS).

Boron did change blood minerals: serum phosphorus was lower than with placebo, serum magnesium was highest in sedentary women given boron, and exercise blunted the fall in phosphorus (Meacham 1995). The trial was small, the women were near peak bone mass, and the abstracts give no BMD numbers by group, so it cannot rule out an effect in older adults with bone loss.

In 134 Korean women with an average age of 41, estimated boron intake averaged about 0.93 mg a day and was not significantly related to bone density in the lumbar spine (L1-L4) or femoral region (Kim 2008). In 66 postmenopausal Jordanian women already diagnosed with osteoporosis, estimated boron intake (mean 3.3 mg a day) correlated with BMD taken from their medical records (p < .05) (Rababah 2024). In 53 Turkish women aged 55-60, those whose drinking water had at least 1 mg/L boron had higher serum osteocalcin, a marker of bone formation, than women with less boron in their water (P ≤ 0.05); that study did not report BMD in its abstract (Boyacioglu 2018).

Studies like these cannot show that boron causes higher bone density. Boron comes mainly from plant foods, so a high intake also tracks a diet rich in fruit, vegetables and legumes (NIH ODS; Kim 2008). The Jordanian study also enrolled only women with osteoporosis (mean T-score -2.99), so the range of bone density it compared was narrow (Rababah 2024).

In the first study, 12 women aged 48-82 ate a diet supplying about 0.25 mg boron a day for 119 days and then took 3 mg a day. Boron markedly reduced urinary calcium and magnesium excretion and raised serum oestradiol and testosterone, more so when magnesium intake was low (Nielsen 1987).

Later studies did not confirm a simple benefit. After 3 weeks on a low-boron diet, 3 weeks of a 3 mg supplement had no effect on minerals, sex steroids or urinary crosslinks (markers of bone breakdown) (Beattie 1993). In 11 women, boron reduced the share of dietary calcium lost in urine on a low-magnesium diet but increased it in women given magnesium supplements (Hunt 1997). In a double-blind study of 13 women, boron lowered oestradiol and progesterone when magnesium was low and did not change osteocalcin or alkaline phosphatase (Nielsen 2004). None of these studies measured bone density.

A 2020 narrative review of 11 human studies (594 participants, 7 of boron alone and 4 with other nutrients) concluded that 3 mg a day is useful to help prevent and maintain adequate bone mineral density (Rondanelli 2020), and a 2015 review proposed 3 mg a day for people with or at risk of osteopenia or osteoporosis (Pizzorno 2015). Neither used systematic methods, and the one placebo-controlled bone density trial found no direct effect.

Other assessments are more cautious. NIH ODS concludes that more research is needed to know whether boron supplementation affects bone health in humans, and a 2026 critical review of lithium, silicon and boron found current human data insufficient to justify supplementation (NIH ODS; Melenikioti 2026).

For postmenopausal women and men aged 50 and over, the Bone Health and Osteoporosis Foundation's guide pairs medicine for those at high fracture risk with adequate calcium and vitamin D, avoiding smoking and excessive alcohol, weight-bearing and resistance exercise, and fall prevention (LeBoff 2022). For postmenopausal women with osteoporosis, the American College of Physicians recommends bisphosphonates as first treatment, and an individual decision for women over 65 with low bone mass (Qaseem 2023).

Among supplements, see the evidence for vitamin D and calcium for bone density.

At 3 mg a day, boron is far below the US tolerable upper intake level of 20 mg a day for adults, which also applies in pregnancy and breastfeeding; the limit is based on reproductive and developmental effects in animals (NIH ODS). The European limit is 10 mg a day (Rondanelli 2020). Children's limits are lower: 3 mg a day at ages 1-3, 6 mg at 4-8, 11 mg at 9-13 and 17 mg at 14-18 (NIH ODS). No upper limit is set for infants: breast milk, formula and food should be their only sources of boron, and high intakes have caused anaemia and seizures in infants (NIH ODS). The 3 mg dose studied in adults equals the limit for children aged 1-3. In an 8-week trial of 10 mg a day as boric acid or boron citrate in 60 adults with kidney stones, the only significant lab change was higher urine phosphorus with boric acid, and no other clinically relevant effects were seen; the trial was too small and short to establish long-term safety (Vousoughi 2025).

Nearly all boron eaten is excreted, and urine boron tracks intake (Hunt 1997; NIH ODS); boron toxicity can cause kidney injury (NIH ODS), so people with kidney disease should ask before taking it. Boron's effects on sex hormones have been inconsistent, raising oestradiol and testosterone in one study and lowering oestradiol in another (Nielsen 1987; Nielsen 2004), so check first if you have a hormone-sensitive condition or take hormone therapy.

NIH ODS lists no clinically relevant interactions between boron and medicines. The practical conflicts are counting boron across products, its inconsistent effect on sex hormones (Nielsen 1987; Nielsen 2004), and the magnesium-dependent effect on urinary calcium seen in one metabolic study (Hunt 1997). No study has tested boron alongside osteoporosis medicines.